PD-L1 as a biomarker of response to immune-checkpoint inhibitors-Reference-Cited by-同舟云学术

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

Published:2021-02-12 Issue:6 Volume:18 Page:345-362
ISSN:1759-4774
Container-title:Nature Reviews Clinical Oncology
language:en
Short-container-title:Nat Rev Clin Oncol

Author:

Doroshow Deborah Blythe,Bhalla Sheena,Beasley Mary Beth,Sholl Lynette M.,Kerr Keith M.,Gnjatic Sacha^ORCID,Wistuba Ignacio I.,Rimm David L.^ORCID,Tsao Ming Sound,Hirsch Fred R.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://www.nature.com/articles/s41571-021-00473-5.pdf

Reference199 articles.

1. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).

2. Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450–461 (2015).

3. Blank, C., Gajewski, T. F. & Mackensen, A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol. Immunother. 54, 307–314 (2005).

4. Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99, 12293–12297 (2002).

5. Gong, J., Chehrazi-Raffle, A., Reddi, S. & Salgia, R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J. Immunother. Cancer 6, 8 (2018).

Cited by 845 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Orchestrated metal-coordinated carrier-free celastrol hydrogel intensifies T cell activation and regulates response to immune checkpoint blockade for synergistic chemo-immunotherapy;Biomaterials;2025-01

2. Nano-enabled regulation of DNA damage in tumor cells to enhance neoantigen-based pancreatic cancer immunotherapy;Biomaterials;2024-12

3. Engineering PD-L1 targeted liposomal canagliflozin achieves multimodal synergistic cancer therapy;Chemical Engineering Journal;2024-10

4. Dual-signal output biosensor for the detection of program death-ligand 1 and therapy progress monitoring of cancer;Biosensors and Bioelectronics;2024-10

5. Simulating CD8 T Cell Exhaustion: A Comprehensive Approach;2024-09-11